These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36471215)

  • 1. Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials.
    Takamizawa S; Katsuya Y; Chen YN; Mizuno T; Koyama T; Sudo K; Yoshida T; Kondo S; Iwasa S; Yonemori K; Shimizu T; Yamamoto N; Suzuki S
    Invest New Drugs; 2023 Feb; 41(1):173-181. PubMed ID: 36471215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
    Shin E; Lim DH; Han J; Nam DH; Park K; Ahn MJ; Kang WK; Lee J; Ahn JS; Lee SH; Sun JM; Jung HA; Chung TY
    BMC Ophthalmol; 2020 Jan; 20(1):19. PubMed ID: 31918686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular toxicity of targeted therapies.
    Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
    J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
    Subbiah IM; Wheler JJ; Hess KR; Hong DS; Naing A; Fu S; Kurzrock R; Tsimberidou AM
    Int J Cancer; 2017 Jan; 140(1):208-215. PubMed ID: 27599876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.
    Niraula S; Amir E; Vera-Badillo F; Seruga B; Ocana A; Tannock IF
    J Clin Oncol; 2014 Nov; 32(32):3634-42. PubMed ID: 25267757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
    Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
    Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular side effects of checkpoint inhibitors.
    Alba-Linero C; Alba E
    Surv Ophthalmol; 2021; 66(6):951-959. PubMed ID: 33440195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
    Kanjanapan Y; Day D; Butler MO; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S; Chappell M; Chow K; Sherwin B; Stayner LA; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A
    Eur J Cancer; 2019 Jan; 107():1-7. PubMed ID: 30529898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.
    Abdel-Rahman O; Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):387-394. PubMed ID: 28277102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist.
    Canino F; Omarini C; Cerma K; Moscetti L; Tornincasa A; Trudu L; Dominici M; Piacentini F
    Clin Breast Cancer; 2022 Jun; 22(4):289-299. PubMed ID: 35246390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular toxicities of MEK inhibitors and other targeted therapies.
    Stjepanovic N; Velazquez-Martin JP; Bedard PL
    Ann Oncol; 2016 Jun; 27(6):998-1005. PubMed ID: 26951625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
    Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
    J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
    Banerji U; van Herpen CML; Saura C; Thistlethwaite F; Lord S; Moreno V; Macpherson IR; Boni V; Rolfo C; de Vries EGE; Rottey S; Geenen J; Eskens F; Gil-Martin M; Mommers EC; Koper NP; Aftimos P
    Lancet Oncol; 2019 Aug; 20(8):1124-1135. PubMed ID: 31257177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
    Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
    J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.
    Kunkler AL; Binkley EM; Mantopoulos D; Hendershot AJ; Ohr MP; Kendra KL; Davidorf FH; Cebulla CM
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1771-1781. PubMed ID: 31098752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.
    Shimomura A; Kondo S; Kobayashi N; Iwasa S; Kitano S; Tamura K; Fujiwara Y; Yamamoto N
    Int J Clin Oncol; 2017 Aug; 22(4):780-785. PubMed ID: 28293794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.